Company / SG&A per Share
Corcept Therapeutics Incorporated SG&A per Share History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A per Share
$4.27
FY2025
5-year range
$0.86 / $4.27
FY2021-FY2025
Trend
+57.5%
vs FY2024
Sector context
#41 of 210
Health Care
What the data says
Corcept Therapeutics Incorporated's sg&a per share of $4.27 is higher than 80% of companies in the Health Care sector (FY2025). SG&A per Share has increased for 7 consecutive years, from $0.39 in FY2018 to $4.27 in FY2025.
Based on SEC 10-K filings.
4.27 in FY2025 with a 5-year CAGR of +43.2%. Top quartile in the Health Care sector.
Increased from $1.71 to $4.27 over the past 2 years.
Health Care sector context is included.
SG&A per Share over time
Growth rates
- 3-Year CAGR
- +62.5%
- 5-Year CAGR
- +43.2%
- 10-Year CAGR
- -
Sector benchmark
-85.5% below sector average
Key checks
Key Insights
- Corcept Therapeutics Incorporated's sg&a per share has grown for 7 consecutive years.
- In FY2025, sg&a per share increased 57.5% year-over-year.
- Ranks #41 out of 210 companies in the Health Care sector.
- Lowest sg&a per share in the period was in FY2016.
Company context
Key Data Points
- Altman Z-Score 3.44 (safe zone, above 2.9 threshold)
- Strong profit margin: 20.9%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $4.27 | +57.5% |
| FY2024 | $2.71 | +58.7% |
| FY2023 | $1.71 | +71.9% |
| FY2022 | $0.99 | +15.6% |
| FY2021 | $0.86 | +21.1% |
| FY2020 | $0.71 | +30.8% |
| FY2019 | $0.54 | +37.6% |
| FY2018 | $0.39 | -28.8% |
| FY2017 | $0.55 | +73.9% |
| FY2016 | $0.32 | -12.6% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026